ClinicalTrials.gg
CompletedNCT00923988Updated Aug 11, 2009

Effect of Passive Smoking on Platelet Function and Endothelial Function

An interventional study of secondhand smoke exposure in Endothelial Function and Platelet Aggregation, sponsored by Kantonsspital Graubünden. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-11.

Sponsored by Kantonsspital Graubünden · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Passive smoking is associated with an increased risk for cardiovascular events. However, the exact mechanisms by which passive smoking affects cardiovascular health are not entirely understood. In the present study, the researchers investigate the effects of short-term exposure to secondhand smoke on platelet function and peripheral microvascular endothelial function in healthy individuals. For this purpose, platelet function and endothelial function are measured before and after a 1-hour exposure to secondhand smoke in a concentration that is encountered in bars and restaurants without smoke-free policies. The researchers' hypothesis is that short-term exposure leads to platelet activation and impairment of endothelial function.

02

Conditions studied

  • Endothelial Function
  • Platelet Aggregation

Keywords

  • Secondhand smoke
  • passive smoking
  • platelet function
  • endothelial function
03

In context

Lead sponsor

Kantonsspital Graubünden is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy individuals
  • nonsmokers
  • no regular medication (in particular no drugs affecting platelet function or vascular function)

Exclusion criteria

Exclusion Criteria:

  • exposition to secondhand smoke within 1 week before inclusion
  • use of drugs affecting platelet function or vascular function within 1 week before study inclusion
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Interventions

  • Othersecondhand smoke exposure

    Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.

06

What researchers measure

Primary outcomes

  1. Change in platelet aggregation and/or endothelial function

    Time frame: 12-24 hours

07

Study locations

1 site
  • Kantonsspital Graubuenden
    Chur, 7000, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00923988
Lead sponsor
Kantonsspital Graubünden
First posted
Jun 18, 2009
Start date
Jun 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Aug 11, 2009

Study contacts

Piero O. Bonetti, MD
principal investigator · Division of Cardiology, Department of Internal Medicine, Kantonsspital Graubuenden, Loestrasse 170, CH-7000 Chur, Switzerland
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion